235 related articles for article (PubMed ID: 33446568)
1. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer.
Purohit V; Wang L; Yang H; Li J; Ney GM; Gumkowski ER; Vaidya AJ; Wang A; Bhardwaj A; Zhao E; Dolgalev I; Zamperone A; Abel EV; Magliano MPD; Crawford HC; Diolaiti D; Papagiannakopoulos TY; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Feb; 35(3-4):218-233. PubMed ID: 33446568
[TBL] [Abstract][Full Text] [Related]
2. aPKCĪ¹ promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
3. ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.
Wang L; Yang H; Zamperone A; Diolaiti D; Palmbos PL; Abel EV; Purohit V; Dolgalev I; Rhim AD; Ljungman M; Hadju CH; Halbrook CJ; Bar-Sagi D; di Magliano MP; Crawford HC; Simeone DM
Genes Dev; 2019 Jun; 33(11-12):641-655. PubMed ID: 31048544
[TBL] [Abstract][Full Text] [Related]
4. iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding.
Ge W; Zhao K; Wang X; Li H; Yu M; He M; Xue X; Zhu Y; Zhang C; Cheng Y; Jiang S; Hu Y
Cancer Cell; 2017 Nov; 32(5):561-573.e6. PubMed ID: 29033244
[TBL] [Abstract][Full Text] [Related]
5. FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling.
Guan L; Zhang L; Gong Z; Hou X; Xu Y; Feng X; Wang H; You H
Hepatology; 2016 Jun; 63(6):1914-27. PubMed ID: 26857210
[TBL] [Abstract][Full Text] [Related]
6. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.
Zhang P; Singh A; Yegnasubramanian S; Esopi D; Kombairaju P; Bodas M; Wu H; Bova SG; Biswal S
Mol Cancer Ther; 2010 Feb; 9(2):336-46. PubMed ID: 20124447
[TBL] [Abstract][Full Text] [Related]
7. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
8. UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.
Abu-Alainin W; Gana T; Liloglou T; Olayanju A; Barrera LN; Ferguson R; Campbell F; Andrews T; Goldring C; Kitteringham N; Park BK; Nedjadi T; Schmid MC; Slupsky JR; Greenhalf W; Neoptolemos JP; Costello E
J Pathol; 2016 Feb; 238(3):423-33. PubMed ID: 26497117
[TBL] [Abstract][Full Text] [Related]
9. RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding.
Wan ZH; Jiang TY; Shi YY; Pan YF; Lin YK; Ma YH; Yang C; Feng XF; Huang LF; Kong XN; Ding ZW; Tan YX; Dong LW; Wang HY
Hepatology; 2020 Jun; 71(6):2005-2022. PubMed ID: 31541481
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
11. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
12. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
Panieri E; Saso L
Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
[No Abstract] [Full Text] [Related]
14. Keap1-Nrf2 signalling in pancreatic cancer.
Hayes AJ; Skouras C; Haugk B; Charnley RM
Int J Biochem Cell Biol; 2015 Aug; 65():288-99. PubMed ID: 26117456
[TBL] [Abstract][Full Text] [Related]
15. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
[TBL] [Abstract][Full Text] [Related]
16. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway.
Zhou Y; Chen Y; Shi Y; Wu L; Tan Y; Li T; Chen Y; Xia J; Hu R
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719368
[TBL] [Abstract][Full Text] [Related]
17. GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling.
Chen T; Jinlin D; Wang F; Yuan Z; Xue J; Lu T; Huang W; Liu Y; Zhang Y
Cancer Lett; 2022 Jul; 538():215692. PubMed ID: 35487311
[TBL] [Abstract][Full Text] [Related]
18. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.
Jeddi F; Soozangar N; Sadeghi MR; Somi MH; Samadi N
DNA Repair (Amst); 2017 Jun; 54():13-21. PubMed ID: 28415030
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
20. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
